Submit to Special Issue Submit Abstract to Special Issue Review for Vaccines Propose a Special Issue

Journal Menu

Journal Browser

Immune Response After Respiratory Infection or Vaccination

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Innate and Adaptive Immunity in Vaccination".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 10080

Share This Special Issue

Special Issue Editor

Dr. Dingmei Zhang

E-Mail Website
Guest Editor

Department of Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China
Interests: infectious disease epidemiology; evaluation of vaccine efficacy; vaccine development
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The immune response to respiratory tract infections or vaccination is complex, highlighting the need to better understand this multifaceted response. The occurrence of different pathogens, strains, and variants, as well as their potential for co-circulation, add to the complexity of this dynamic environment. In this Special Issue, we will explore the latest developments in understanding the immune or vaccine response, including the diagnosis and detection of clinical respiratory infections. Key topics may include the following:

The temporal dynamics of the immune response to pathogen co-infections;
Key factors influencing pathogen clearance;
Factors contributing to the formation and development of immune memory in response to co-infections;
The examination of respiratory tract pathogen vaccines and their protection of the host in the context of co-infection.

This Special Issue aims to provide a significant platform for cutting-edge research and insights.

Dr. Dingmei Zhang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

immune response to viral co-infections
immune memory in response to co-infections
influenza and coronavirus vaccines
vaccines for co-infections

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (9 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

14 pages, 635 KiB

Open AccessArticle

Specific Features of Immune Response in Patients with Different Asthma Endotypes Following Immunization with a Conjugate Pneumococcal Vaccine

by Anton M. Kostinov, Anna Yu. Konishcheva, Andrey D. Protasov, Mikhail P. Kostinov, Valentina B. Polishchuk, Alexander V. Zhestkov, Natalia E. Yastrebova, Aristitsa M. Kostinova, Zhanar Sh. Musagulova and Ekaterina V. Prutskova

Vaccines 2025, 13(5), 459; https://doi.org/10.3390/vaccines13050459 - 25 Apr 2025

Viewed by 136

Abstract

Background: Asthma is a heterogeneous disease characterized by variable bronchial obstruction, hyper-responsiveness, and inflammation. Evaluating the immunological changes following pneumococcal immunization in patients with different asthma endotypes is of great importance. This study aimed to evaluate the effects of PCV13 on the clinical parameters and the changes over time in the levels of the main cytokines in asthma patients. Methods: This was a single-center, open-label, non-randomized, prospective, cohort, controlled study of 31 patients aged 18 to 80 with a known diagnosis of asthma. The study subjects were given one injection of PCV13. Their clinical parameters and serum concentrations of certain Th1/Th2/Treg cytokines were assessed over a year following the vaccination. Results: Compared to the pre-vaccination period, there was an 81.5% reduction in the number of patients with asthma exacerbations (p < 0.001), a 76.5% increase in the number of patients free from hospitalization (p < 0.001), and an improvement in the level of asthma control. Positive changes were observed both in patients with T2-high and T2-low asthma; however, only those with T2-low asthma showed a significant improvement in the level of asthma control. Significant changes were reported for IFN-γ: its serum concentrations increased six weeks following the vaccination (p < 0.05), primarily in patients with T2-high asthma. Conclusions: In asthma patients, immunization with PCV13 was clinically effective, irrespective of the asthma endotype. Its clinical effects were accompanied by a reduction in the rates of exacerbations and hospitalizations and an increase in IFN-γ serum levels. This finding suggests that this cytokine plays an important role in restoring immune response in asthma patients. Full article

(This article belongs to the Special Issue Immune Response After Respiratory Infection or Vaccination)

► Show Figures

Figure 1

16 pages, 6590 KiB

Open AccessArticle

Vaccine Efficacy of a Replication-Competent Interferon-Expressing Porcine Reproductive and Respiratory Syndrome (PRRS) Virus Against NADC-34 Challenge

by Laura C. Miller, Sarah J. Anderson, Alexandra C. Buckley, Erin E. Schirtzinger, Mahamudul Hasan, Kaitlyn M. Sarlo Davila, Damarius S. Fleming, Kelly M. Lager, Jiuyi Li and Yongming Sang

Vaccines 2025, 13(4), 413; https://doi.org/10.3390/vaccines13040413 - 15 Apr 2025

Viewed by 349

Abstract

Background/Objectives: Porcine reproductive and respiratory syndrome virus (PRRSV) significantly impedes swine production due to rapid genetic variation and suppression of antiviral interferon (IFN) responses, leading to ineffective immunity. To address this, we developed IFNmix, a replication-competent PRRSV modified live vaccine (MLV) candidate co-expressing three Type I IFN subclasses (IFNα, IFNβ, IFNδ) to enhance antiviral immunity. Methods: In two independent in vivo experiments, we compared the protection of IFNmix and a commercial PRRSV MLV vaccine during challenge with a virulent PRRSV strain. Clinical signs, antibody and cytokine production, viral replication, and lung pathology in IFNmix-vaccinated pigs were compared to those of commercial PRRSV vaccines and controls. Results: Pigs vaccinated with IFNmix exhibited similar anti-PRRSV antibody development, serum viral loads, lung lesions, and cytokine responses post-challenge with the virulent NADC34 strain, with comparable or lower body temperatures and weight gain, to pigs vaccinated with the commercial vaccines. While IFNmix showed early viral load reduction compared to the commercial vaccine (Days 7–14 post-challenge), it demonstrated similar efficacy in controlling PRRSV replication and lung pathology. Conclusions: These findings suggest that IFNmix, by expressing multiple IFNs, can potentially enhance innate and adaptive immune responses, offering a promising approach to improving PRRSV vaccine efficacy. Further studies are needed to evaluate IFNmix against a broader range of PRRSV strains and to optimize its attenuation and immunogenicity. Full article

(This article belongs to the Special Issue Immune Response After Respiratory Infection or Vaccination)

► Show Figures

Figure 1

9 pages, 619 KiB

Open AccessArticle

Early and Late Influenza Vaccine Effectiveness in South Korea During the 2023–2024 Season

by Yu Jung Choi, Joon Young Song, Seong-Heon Wie, Jacob Lee, Jin-Soo Lee, Hye Won Jeong, Joong Sik Eom, Jang Wook Sohn, Won Suk Choi, Eliel Nham, Jin Gu Yoon, Ji Yun Noh, Hee Jin Cheong and Woo Joo Kim

Vaccines 2025, 13(2), 197; https://doi.org/10.3390/vaccines13020197 - 17 Feb 2025

Viewed by 826

Abstract

Background: During the 2023–2024 season, the influenza epidemic in South Korea peaked earlier, and the influenza vaccination rate among individuals aged ≥ 65 was high (82.2%). However, data on real-world vaccine effectiveness against influenza are lacking. Methods: From November 2023 to April 2024, we conducted a multicenter retrospective case–control study on adult patients aged ≥ 18 years who presented with influenza-like illness at seven medical centers as a part of a hospital-based influenza morbidity and mortality surveillance (HIMM) program in South Korea. Demographic and clinical data were collected from questionnaire surveys and electronic medical records. Using a test-negative design, we assessed the effectiveness of the 2023–2024 seasonal influenza vaccine, with age, sex, and comorbidities included as covariates. Results: A total of 3390 participants were enrolled through the HIMM system, including 1695 patients with either rapid antigen test (RAT) or real-time reverse-transcription polymerase chain reaction (RT-PCR) positive results and controls matched for age, sex, and months of registration. Among the 1696 influenza-positive patients, 1584 (93.5%) underwent RAT, with 88.9% testing positive for influenza A and 11.1% for influenza B. During the study periods, the overall vaccine effectiveness (VE) was 24.3% (95% confidence interval (CI), 11.5 to 35.2). The VE was insignificant when limited to older adults aged ≥ 65 years (13.5%; 95% CI, −17.9 to 36.6). In the subgroup analysis by subtype, the VE was 19.0% (95% CI, 5.0 to 31.0) for influenza A and 56.3% (95% CI, 35.3 to 70.6) for influenza B. Notably, influenza VE was 20.4% (95% CI, 2.9 to 34.8) in the early period (November to December) but decreased to 12.4% (95% CI, −14.9 to 33.2) in the late period (January to April). Conclusion: During the 2023–2024 season, the influenza vaccine showed a modest effectiveness (24.3%) against laboratory-confirmed influenza, which was particularly higher for influenza B. Because the VE was insignificant in older adults, particularly during the late period, better immunogenic influenza vaccines with longer-lasting protection should be considered. Full article

(This article belongs to the Special Issue Immune Response After Respiratory Infection or Vaccination)

► Show Figures

Figure 1

18 pages, 2554 KiB

Open AccessArticle

Anti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus

by Shreya Mukhopadhyay, Ioannis Manolaridis, Christopher Warren, Aimin Tang, Gregory O’Donnell, Bin Luo, Ryan P. Staupe, Kalpit A. Vora and Zhifeng Chen

Vaccines 2025, 13(1), 35; https://doi.org/10.3390/vaccines13010035 - 2 Jan 2025

Viewed by 1469

Abstract

Background/Objectives: The respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in children and adults. With nearly everyone infected by the age of five, there is an opportunity to develop booster vaccines that enhance B-cell immunity, promoting potent and broadly neutralizing antibodies. One potential approach involves using anti-idiotypic antibodies (anti-IDs) to mimic specific antigenic sites and enhance preexisting immunity in an epitope-specific manner. RB1, a monoclonal antibody (mAb) that binds to site IV of the RSV fusion (RSV F) protein, is a potent and broadly neutralizing against RSV A and B viruses. It is the precursor for MK1654 (clesrovimab), which successfully completed a Phase III clinical trial. Methods: In this study, we isolated two anti-IDs, 1A6 and 1D4, targeting RB1 CDR regions, demonstrating that 1A6 competes fully with RSV F in binding to RB1. Results: We resolved the RB1-1A6 and RB1-1D4 Fab-Fab complex structures and proved that 1A6 mimics the RSV F site IV better than 1D4. In an immunogenicity study, mice primed with RSV F and boosted with 1A6 Fab showed a site IV-specific antibody response with a concurrent increase in RSV virus neutralization. Conclusions: These results suggest that anti-IDs could be potentially used as booster vaccines for specific epitopes. Full article

(This article belongs to the Special Issue Immune Response After Respiratory Infection or Vaccination)

► Show Figures

Figure 1

17 pages, 2922 KiB

Open AccessArticle

Longitudinal Comparison of Three T-Cell Assays and Three Antibody Assays Against SARS-CoV-2 Following Homologous mRNA-1273/mRNA-1273/mRNA-1273 and Heterologous ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naïve Healthcare Workers

by Hyeyoung Lee, Geon Young Ko, Jihyun Lee, Hyunjoo Bae, Ji Hyeong Ryu, Jin Jung, Hyunhye Kang, Raeseok Lee, Dong-Gun Lee and Eun-Jee Oh

Vaccines 2024, 12(12), 1350; https://doi.org/10.3390/vaccines12121350 - 29 Nov 2024

Viewed by 996

Abstract

Background: Cellular and humoral immunity are key to the immune response against SARS-CoV-2, but the comparability and correlation across different assays remain underexplored. This study compares three T-cell and three antibody assays in two vaccine groups. Methods: This prospective longitudinal cohort study involved 46 naïve healthcare workers: a total of 11 in the homologous mRNA-1273 group (three doses) and 35 in the heterologous ChAd group (two ChAd doses followed by a BNT booster). Blood samples were collected at five time points. Cellular immunity was assessed using ELISPOT and two commercial interferon-gamma release assays: (IGRA)-QuantiFERON SARS-CoV-2 (QF) and Covi-FERON ELISA (CoVF). Humoral immunity was evaluated using total and IgG antibody assays and a surrogate virus neutralization test. Results: The mRNA-1273 group exhibited stronger and more consistent responses than the ChAd group. The correlations between ELISPOT and IGRA varied from weak to moderate (ρ = 0.300–0.410), while QF-IGRA and CoVF-IGRA showed stronger correlations (ρ = 0.700–0.737). The ELISPOT assay showed substantial agreement with QF [Ag2]-IGRA (k = 0.697–0.774) and CoVF [O-sp]-IGRA (k = 0.641–0.718), and an 80.4% agreement rate (k = 0.608) was found between the QF [Ag2]- and CoVF [O-sp]-IGRA tests. Three antibody assays demonstrated very strong correlations with each other and substantial to near-perfect agreement with ELISPOT (k = 0.866–0.949), QF [Ag2]-IGRA (k = 0.807–0.831), and CoVF [O-sp]-IGRA (k = 0.753–0.777). Conclusions: SARS-CoV-2-specific cellular and antibody responses vary by platform and vaccine type, highlighting the importance of measuring both T-cell and B-cell responses using multiple assays to comprehensively assess immune status. Full article

(This article belongs to the Special Issue Immune Response After Respiratory Infection or Vaccination)

► Show Figures

Figure 1

16 pages, 260 KiB

Open AccessArticle

Knowledge, Attitudes, and Practices towards Influenza Vaccine among Guangzhou Residents: A Cross-Sectional Study

by Jiawen Xu, Jianyun Lu, Qing He, Yu Ma, Keyi Wu, Haowen Chen, Xiaowei Ma and Xianbo Wu

Vaccines 2024, 12(10), 1169; https://doi.org/10.3390/vaccines12101169 - 14 Oct 2024

Viewed by 1495

Abstract

Background: Influenza vaccination is an important prevention strategy for flu illness. However, the vaccination rate is still low in Guangzhou, China. This study aimed to understand the status of knowledge, the attitude towards the vaccines’ reliability and safety, and other aspects associated with the willingness and practice of influenza vaccines in the pediatric and adult populations of Guangzhou city. Methods: This study was performed in eleven districts in Guangzhou between November 2020 and December 2020, including the Yuexiu, Liwan, Haizhu, Tianhe, Baiyun, Panyu, Huadu, Nansha, Huangpu, Zengcheng, and Conghua districts. The parents of children and teenagers under the age of eighteen in Guangzhou were surveyed using self-administered questionnaires in four domains: demographic information, the knowledge status and perception of influenza vaccination, the willingness and attitude towards influenza vaccination, and previous vaccine uptake. A multivariable logistic regression was employed to assess the possible determinants of willingness and practice to receive influenza vaccination, calculating the odds ratios (ORs) and 95% confidence interval (CI). A two-sided p-value < 0.05 was deemed statistically significant. Results: A total of 13,213 valid questionnaires were collected (validity rate 98.8%). Out of these participants, 42.62% (5631 participants) expressed a willingness to receive the influenza vaccine, while 55.40% (7320 participants) reported that their children and teenagers had been vaccinated against the flu. Furthermore, 40.44% of the respondents (5343 participants) or other family members had received the influenza vaccine. Logistic regression indicated that factors such as being female (OR = 1.395, 95% CI: 1.278–1.522), being involved in the work of COVID-19 prevention and control (1.551, 1.396–1.724), affirming the preventive effects of vaccination (2.474, 2.106–2.906), knowing about annual influenza vaccination (2.756, 2.540–2.992), and understanding prioritized influenza vaccination populations (1.464, 1.343–1.596) were all positively associated with vaccination willingness. Conversely, middle-aged persons (aged 40–49 years old) (0.726, 0.617–0.853), higher educational levels (undergraduate versus middle school) (0.858, 0.768–0.959), heightened concerns about vaccine safety (considering side effects are obvious versus considering it is safe and basically no side effects) (0.284, 0.188–0.429) and lower knowledge scores (0.813, 0.701–0.942) were adversely linked with vaccination willingness. Conclusion: These findings provide essential insights for altering the perception of influence and influenza vaccination, as well as enhancing health communication strategies to improve influenza vaccine uptake among Guangzhou residents. Full article

(This article belongs to the Special Issue Immune Response After Respiratory Infection or Vaccination)

13 pages, 2401 KiB

Open AccessArticle

Have Previous COVID-19 Vaccinations Shaped the Potential Enhancing Infection of Variant Strains?

by Husheng Xiong, Xiang Meng, Yanqin Song, Jiayi Zhong, Shuang Liu, Xun Zhu, Xin Ye, Yonghui Zhong and Dingmei Zhang

Vaccines 2024, 12(6), 567; https://doi.org/10.3390/vaccines12060567 - 22 May 2024

Cited by 2 | Viewed by 2451

Abstract

Objective: This study aimed to investigate the infection status of Omicron in the population and the association between COVID-19 vaccination and infection with Omicron. Methods: We conducted a cross-sectional study to openly recruit participants for a survey of SARS-CoV-2 infection by convenience sampling from 1 January to 15 January 2023 after a COVID-19 pandemic swept across China. Additionally, the binary logistic regression model was adopted to evaluate the association between COVID-19 vaccination and the infection outcomes or symptom severity, respectively. Meanwhile, the relations between the vaccination and duration of the symptoms were estimated via ordinal logistic analysis. Results: Of the 2007 participants, the prevalence of infection with Omicron was 82.9%. Compared with unvaccinated individuals, inactivated COVID-19 vaccination could increase the risk of Omicron infection (OR = 1.942, 95% CI: 1.093–3.448), and the receipt of at least one dose of non-inactivated COVID-19 vaccines was a protective factor against infection (OR = 0.428, 95% CI: 0.226–0.812). By contrast, no relations were observed in COVID-19 vaccination with the symptoms of infection and duration of symptoms (p > 0.05). Conclusions: This cross-sectional study concluded that inactivated COVID-19 vaccination might increase the risk of Omicron infection, which should be a concern during COVID-19 vaccination and the treatment of variant infections in the future, and the receipt of at least one dose of non-inactivated COVID-19 vaccine was a protective factor against infection. Full article

(This article belongs to the Special Issue Immune Response After Respiratory Infection or Vaccination)

► Show Figures

Figure 1

Review

Jump to: Research

25 pages, 645 KiB

Open AccessReview

Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review

by Pan-Pan Wu and Fang-Rui Ding

Vaccines 2025, 13(5), 470; https://doi.org/10.3390/vaccines13050470 - 27 Apr 2025

Viewed by 162

Abstract

Respiratory syncytial virus (RSV) is the primary etiological agent responsible for lower respiratory tract infections (LRTIs) and hospitalizations among infants. Nirsevimab, a novel monoclonal antibody (mAb), offers sustained protection against RSV for a minimum of 5 months in neonates and young children. Extensive clinical trials and real-world evidence have demonstrated that nirsevimab significantly mitigates the incidence and severity of RSV infections in infants, while exhibiting favorable safety profiles and cost-effectiveness. Regulatory authorities in multiple countries have approved nirsevimab, and its implementation is progressively expanding across various healthcare settings. However, several critical issues require further attention. Specifically, a more in-depth investigation into the long-term efficacy and benefits of nirsevimab across diverse populations, particularly neonates, is essential. Additionally, accelerating the introduction and administration of nirsevimab in developing countries remains imperative. Thus, this review comprehensively summarizes the administration of nirsevimab in infants to facilitate its broader application. Full article

(This article belongs to the Special Issue Immune Response After Respiratory Infection or Vaccination)

► Show Figures

Figure 1

15 pages, 1839 KiB

Open AccessReview

Current Status and Significance of Additional Vaccination with COVID-19 Vaccine in Japan—Considerations from Antibody Levels from Hybrid Immunity and Public Perceptions

by Hiroshi Kusunoki

Vaccines 2024, 12(12), 1413; https://doi.org/10.3390/vaccines12121413 - 15 Dec 2024

Viewed by 1790

Abstract

This report examines the evolving role of coronavirus disease 2019 (COVID-19) vaccination in Japan, especially in light of the reduced public concern following the reclassification of COVID-19 as a Category 5 infectious disease in May 2023. With over half the population estimated to have hybrid immunity from prior infections and vaccinations, this report evaluated the necessity and frequency of additional booster doses. Despite strong recommendations from Japanese medical societies to continue vaccination, public skepticism remains owing to financial burdens, adverse reactions, and the perceived limited benefits of frequent boosters. Studies on antibody responses have revealed that individuals with hybrid immunity maintain robust protection with significantly elevated antibody titers that persist over extended periods. Case studies have indicated durable immunity among individuals who have both been vaccinated and experienced breakthrough infections, raising questions about the need for uniform booster policies. This report also discusses the newly approved replicon-type (self-amplifying) vaccines currently available only in Japan, which have generated public and professional debates regarding their efficacy and safety. A more personalized approach to vaccination that takes into account the antibody titers, prior infection history, and individual choices is recommended. Finally, this report underscores the importance of aligning vaccination policies with scientific evidence and public sentiment to optimize COVID-19 countermeasures in Japan. Full article

(This article belongs to the Special Issue Immune Response After Respiratory Infection or Vaccination)

► Show Figures

Journal Menu

Journal Browser

Immune Response After Respiratory Infection or Vaccination

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (9 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI